CM
DNLI icon

Capula Management’s Denali Therapeutics DNLI Stock Holding History

Capula Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38,720
Closed -$799K – 373
2023
Q3 		$799K Buy
+38,720
New +$982K 0.02% 264

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capula Management's DNLI Position: Q4 2023 in Review

Capula Management sold out of Denali Therapeutics (DNLI) in Q4 2023, closing a stake of 38,720 shares — an estimated $799K sold.

Capula Management first reported a position in DNLI in Q3 2023 and held it in 1 quarter. The position peaked at $799K in Q3 2023. 209 funds tracked by Wall St. Rank hold DNLI as of Q4 2023.

  • Capula Management reported no remaining Denali Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Capula Management sold 38,720 Denali Therapeutics shares in Q4 2023, an estimated $799K.
  • Capula Management first reported a position in Denali Therapeutics in Q3 2023 and held it in 1 quarter.
  • Capula Management's Denali Therapeutics position peaked at $799K in Q3 2023.
  • 209 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2023.

Based on Capula Management's 13F filing for Q4 2023, filed 12 Feb 2024.